Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 6 (2009), Issue 11 (November)

1. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
   Lancet, 374(9700): 1503-11. [Abstract] [Full-text]
2. Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: an fMRI study.
   Brain Cogn, 71(3): 320-7. [Abstract] [Full-text]
3. Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing-remitting multiple sclerosis.
   Brain Cogn, 71(3): 410-5. [Abstract] [Full-text]
4. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
   Neurology, 73(18): 1493-500. [Abstract] [Full-text]
5. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
   Neurology, 73(18): 1485-92. [Abstract] [Full-text]
6. Resistance training improves muscle strength and functional capacity in multiple sclerosis.
   Neurology, 73(18): 1478-84. [Abstract] [Full-text]
7. Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report.
   BMC Neurol, 9: 56. [Abstract] [Full-text]
8. Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection.
   J Immunol Methods, 351(1): 41-5. [Abstract] [Full-text]
9. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS.
   Clin Immunol, 133(3): 364-74. [Abstract] [Full-text]
10. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.
    Lancet Neurol, 8(12): 1111-9. [Abstract] [Full-text]
11. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis.
    Nat Immunol, 10(12): 1252-9. [Abstract] [Full-text]
12. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role.
    Biochem Pharmacol, 79(2): 198-208. [Abstract] [Full-text]
13. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis.
    Neurology, 73(20): 1628-37. [Abstract] [Full-text]
14. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
    Neurology, 73(20): 1624-7. [Abstract] [Full-text]
15. Impact of multiple sclerosis relapses on progression diminishes with time.
    Neurology, 73(20): 1616-23. [Abstract] [Full-text]
16. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    J Neurol Neurosurg Psychiatry, 80(12): 1337-43. [Abstract] [Full-text]
17. MR spectroscopy indicates diffuse multiple sclerosis activity during remission.
    J Neurol Neurosurg Psychiatry, 80(12): 1330-6. [Abstract] [Full-text]
18. Skew in the human caveolin 1 gene upstream purine complex homozygote haplotype compartment in multiple sclerosis.
    J Neuroimmunol, 216(1): 103-7. [Abstract] [Full-text]
19. Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis.
    J Neuroimmunol, 216(1): 98-102. [Abstract] [Full-text]
20. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.
    J Neuroimmunol, 216(1): 113-7. [Abstract] [Full-text]
21. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
    J Immunol, 183(11): 7602-10. [Abstract] [Full-text]
22. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis.
    Acta Neurol Scand, 120(6): 439-41. [Abstract] [Full-text]
23. Hematopoietic stem cell transplantation in multiple sclerosis.
    Acta Neurol Scand, 120(6): 371-82. [Abstract] [Full-text]
24. CTLA4 exon 1 and promoter polymorphisms in patients with multiple sclerosis.
    Acta Neurol Scand, 120(6): 424-9. [Abstract] [Full-text]
25. Association between human herpesvirus 6 and occurrence of multiple sclerosis among Jordanian patients.
    Acta Neurol Scand, 120(6): 430-5. [Abstract] [Full-text]
26. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    J Neuroimmunol, 217(1): 95-101. [Abstract] [Full-text]
27. Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica.
    J Neuroimmunol, 217(1): 74-9. [Abstract] [Full-text]
28. Cognitive aging in patients with multiple sclerosis: a cross-sectional analysis of speeded processing.
    Arch Clin Neuropsychol, 24(8): 761-7. [Abstract] [Full-text]
29. CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population.
    Psychiatry Res, 170(2): 271-2. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.